Madrigal Pharmaceuticals Inc
MDGL
NASDAQ
Biotechnology
$507.56
USD
+0.19 (+0.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.73B
Volume 234.7K
Revenue
$1.28B
TTM
+149.0%
YoY
Gross Margin
98%
TTM
-1.2%
YoY
Net Income
$-325.10M
TTM
-15.3%
YoY
Operating Cash Flow
$-197.72M
TTM
+35.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 212.8 | 287.3 | 321.1 | 311.3 | 364.3 |
YoY Growth | +1353.8% | +362.0% | +210.8% | +126.8% | +71.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 26.8 | 0.0 |
Gross Profit | 212.8 | 287.3 | 321.1 | 284.5 | 364.3 |
Selling, General & Administrative | 196.9 | 209.1 | 240.0 | 268.5 | 289.4 |
Other Operating Expenses | 9.1 | 18.1 | 24.4 | 0.0 | 40.0 |
Total Operating Expenses | 260.0 | 401.2 | 380.7 | 377.2 | 420.6 |
Operating Income | -47.2 | -114.0 | -59.6 | -92.7 | -56.3 |
EBITDA | -46.8 | -113.6 | -59.2 | -92.3 | -55.9 |
Other Income / Expense | -0.0 | -3.1 | -0.1 | -2.1 | -0.8 |
Total Other Income / Expense | 4.9 | -0.2 | 1.0 | -1.7 | -1.6 |
Income Before Income Taxes | -42.3 | -114.2 | -58.6 | -94.4 | -57.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -42.3 | -114.2 | -58.6 | -94.4 | -57.9 |
Consolidated Net Income / Loss | -42.3 | -114.2 | -58.6 | -94.4 | -57.9 |
Net Income Attributable to Common Shareholders | -42.3 | -114.2 | -58.6 | -94.4 | -57.9 |
Basic EPS | -$1.50 | -$5.08 | -$5.36 | -$3.25 | -$1.99 |
Diluted EPS | -$1.50 | -$5.08 | -$5.36 | -$3.25 | -$1.99 |
Basic Shares Outstanding | 28.2M | 22.5M | 10.9M | 29.0M | 29.1M |
Diluted Shares Outstanding | 28.2M | 22.5M | 10.9M | 29.0M | 29.1M |